Citation Impact
Citing Papers
Thiazide Diuretics, Potassium, and the Development of Diabetes
2006
Effect of Ramipril on the Incidence of Diabetes
2006
Ageing populations: the challenges ahead
2009 Standout
Enhanced exosome secretion in Down syndrome brain - a protective mechanism to alleviate neuronal endosomal abnormalities
2017
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
2010 Standout
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
2007
Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System
2004
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes
2005
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction
2006
Diabetic retinopathy
2010 Standout
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial
2008
A view on drug resistance in cancer
2019 StandoutNature
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD
2017
Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
2005
The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients
2005
The biology and management of non-small cell lung cancer
2018 StandoutNature
Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection
2005
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
2011 Standout
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
2010 Standout
Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up
2007
The metabolic syndrome
2010 Standout
Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study
2005
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
2009 Standout
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial
2005
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
2005 Standout
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
2010
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)
2005
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
2007 Standout
Chronic kidney disease
2011 Standout
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Colorectal cancer
2019 Standout
Shedding light on the cell biology of extracellular vesicles
2018 Standout
The metabolic syndrome
2005 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
The use of combinations of monoclonal antibodies in clinical oncology
2015
Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis
2010
New-onset diabetes and antihypertensive drugs
2005
The Study of the Effects of Diet on Metabolism and Nutrition (STEDMAN) weight loss project: Rationale and design
2005
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
The Study on COgnition and Prognosis in the Elderly (SCOPE) – Major CV events and stroke in subgroups of patients
2005
Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review
2009 Standout
Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists
2004
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial
2006
Treatment of Hypertension in Patients 80 Years of Age or Older
2008 Standout
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
2015
Thiazide Diuretics in the Treatment of Hypertension
2006
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
2015
Angiotensin II Receptor Blocker-based Therapy in Japanese Elderly, High-risk, Hypertensive Patients
2012
Prevention of Atrial Fibrillation by Way of Abrogation of the Renin-Angiotensin System: A Systematic Review and Meta-Analysis
2008
β-Arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice
2009 StandoutNobel
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
2017
The European Association for the Study of Diabetes
2005
Do angiotensin II receptor blockers increase the risk of myocardial infarction?
2005
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
2008 Standout
Mechanisms for Insulin Resistance: Common Threads and Missing Links
2012 Standout
Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension
2010
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2014 Standout
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis
2005
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
2016
Prevalence of Chronic Kidney Disease in the United States
2007 Standout
Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study
2005
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
2015 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist
2005
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial
2006
Prediabetes: a high-risk state for diabetes development
2012 Standout
The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction
2005
Cardiovascular Outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial
2006
Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure
2004
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Repeatability for Gaussian and non‐Gaussian data: a practical guide for biologists
2010 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention
2005
Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010
2013 Standout
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
2006
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
2010 Standout
The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): Protocol, Patient Characteristics, and Blood Pressure during the First 12 Months
2005
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
2006
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
2015
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
2006 Standout
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
2018 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
2008 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Role of Diuretics in the Prevention of Heart Failure
2006
Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention
2005
Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis.
2010
Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999–2004
2006
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
2013 Standout
Management of High Blood Pressure in Blacks
2010
E-S-QUAL
2004 Standout
Diabetes and Vascular Disease
2003
Mechanisms of Reactive Oxygen Species–Dependent Downregulation of Insulin Receptor Substrate-1 by Angiotensin II
2005
Angiotensin receptor blockers and myocardial infarction: the importance of dosage
2006
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
2006 Standout
Evidence-based medicine in hypertension: what type of evidence?
2005
Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril
2006
Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system
2007
Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
2012 Standout
Works of Lada Mitchell being referenced
Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer
2012
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
2004
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
2004 Standout
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
2014
VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).
2014
Generalized, Linear, and Mixed Models
2003
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)
2013
Applied Multivariate Statistics for the Social Sciences
2003